Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks.

Forman DE, Goyette RE.

Clin Appl Thromb Hemost. 2014 Jan;20(1):5-15. doi: 10.1177/1076029613492010. Epub 2013 Jun 9. Review.

PMID:
23754838
2.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

3.

Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?

Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb F, Valdés M, Lip GY.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10.

6.

'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.

Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G, Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP.

Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.

PMID:
24486284
7.

Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.

Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L.

Circ Arrhythm Electrophysiol. 2012 Oct;5(5):941-8. doi: 10.1161/CIRCEP.112.972869. Epub 2012 Aug 24.

8.

Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ; ORBIT-AF Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):461-9. doi: 10.1161/CIRCOUTCOMES.113.000127. Epub 2013 Jun 11.

9.

Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.

Lip GY.

Am J Med. 2011 Feb;124(2):111-4. doi: 10.1016/j.amjmed.2010.05.007. Epub 2010 Sep 29.

PMID:
20887966
10.

The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study.

Lefebvre MC, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc Nguyen P, Tannenbaum C.

Can J Cardiol. 2016 Feb;32(2):169-76. doi: 10.1016/j.cjca.2015.05.012. Epub 2015 May 27.

PMID:
26277091
11.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
12.

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.

O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED.

Eur Heart J. 2015 Dec 7;36(46):3258-64. doi: 10.1093/eurheartj/ehv476. Epub 2015 Sep 29.

13.

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.

Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7.

14.

Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.

Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14.

15.

Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.

Guo Y, Lip GY, Apostolakis S.

Hosp Pract (1995). 2013 Feb;41(1):71-8. doi: 10.3810/hp.2013.02.1012. Review.

PMID:
23466969
16.

Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort.

Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C.

J Thromb Haemost. 2011 Aug;9(8):1460-7. doi: 10.1111/j.1538-7836.2011.04378.x.

17.

Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants.

Verheugt FW.

Clin Cardiol. 2013 Jun;36(6):312-22. doi: 10.1002/clc.22122. Epub 2013 Apr 8. Review.

18.

Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.

Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GYH.

Chest. 2013 Jan;143(1):179-184. doi: 10.1378/chest.12-0608.

PMID:
22722228
19.

Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.

Garcia DA.

Thromb Res. 2012 Jan;129(1):9-16. doi: 10.1016/j.thromres.2011.09.023. Epub 2011 Oct 21. Review.

PMID:
22018997
20.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933

Supplemental Content

Support Center